<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-104338</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Diabetic nephropathy is the most common cause of end stage renal disease. Approaches targeting angiotensin II significantly delay its progression. However, many patients still need renal replacement therapy. High throughput techniques such as unbiased gene expression profiling and proteomics may identify new therapeutic targets. Cell death is thought to contribute to progressive renal cell depletion in chronic nephropathies. A European collaborative effort recently applied renal biopsy transcriptomics to identify novel mediators of renal cell death in diabetic nephropathy. Twenty-five percent of cell death regulatory genes were up or down regulated in diabetic kidneys. TNF-related apoptosis inducing ligand (TRAIL) and osteoprotegerin had the highest-level of expression. In diabetic nephropathy, tubular cells and podocytes express TRAIL. Inflammatory cytokines, including MIF via CD74, up regulate TRAIL. A high glucose environment sensitized renal cells to the lethal effect of TRAIL, while osteoprotegerin is protective. These results suggest that, in addition to glucose levels, inflammation and TRAIL are therapeutic targets in diabetic nephropathy (AU)</dc:description>
<dc:creator>Santamaría,  B</dc:creator>
<dc:creator>Egido, J</dc:creator>
<dc:creator>Sanz, A</dc:creator>
<dc:creator>Lorz,  C</dc:creator>
<dc:creator>Kretzler,  M</dc:creator>
<dc:creator>Rastaldi, M. P</dc:creator>
<dc:creator>Ruiz-Ortega,  M</dc:creator>
<dc:creator>Ucero,  A. C</dc:creator>
<dc:creator>Ortiz,  A</dc:creator>
<dc:creator>Izquierdo,   M. C</dc:creator>
<dc:creator>Benito-Martín,  A</dc:creator>
<dc:creator>Sánchez-Niño,  M. D</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La nefropatía diabética es la causa más común de enfermedad renal crónica terminal. La modulación terapéutica de la angiotensina II retarda, pero no evita, su progresión. La muerte celular contribuye a la pérdida de masa renal en las nefropatías crónicas. Un consorcio europeo empleó la transcriptómica en biopsias renales para identificar nuevos mediadores implicados en la muerte de la célula renal durante la nefropatía diabética. Un 25% de los genes relacionados con la muerte celular estaban expresados diferencialmente en la nefropatía diabética. TRAIL y osteoprotegerina fueron los genes más sobre expresados, y también estaba aumentado CD74. Las células tubulares y podocitos expresan TRAIL bajo la regulación de citocinas proinflamatorias(MIF vía CD74, TNF). La hiperglucemia sensibiliza a las células renales a la apoptosis inducida por TRAIL, mientras que la osteoprotegerina protege. Estos resultados sugieren que, además de la glucemia, la inflamación y TRAIL pueden ser objetivos terapéuticos en la nefropatía diabética (AU)</dc:description>
<dc:source>Nefrologia;29(1): 13-19, ene.-feb. 2009. ilus</dc:source>
<dc:identifier>ibc-104338</dc:identifier>
<dc:title xml:lang="es">La transcriptómica ilustra nuevas vías letales en la nefropatía diabética</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7124^s22032</dc:subject>
<dc:subject>^d38644^s22032</dc:subject>
<dc:subject>^d52396^s22063</dc:subject>
<dc:subject>^d50497^s22032</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3951^s22032</dc:subject>
<dc:subject>^d30827^s22031</dc:subject>
<dc:subject>^d52338^s22002</dc:subject>
<dc:subject>^d32285</dc:subject>
<dc:type>article</dc:type>
<dc:date>200902</dc:date>
</metadata>
</record>
</ibecs-document>
